about
Social, economic, and health impact of the respiratory syncytial virus: a systematic searchSafety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.Epidemiology of herpes zoster infection among patients treated in primary care centres in the Valencian community (Spain).Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain."Knowledge and attitudes of Spanish adolescent girls towards human papillomavirus infection: where to intervene to improve vaccination coverage".Comparison between diagnosis and treatment of community-acquired pneumonia in children in various medical centres across Europe with the United States, United Kingdom and the World Health Organization guidelines.Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain).The impact of childhood acute rotavirus gastroenteritis on the parents' quality of life: prospective observational study in European primary care medical practices.Gut microbiota in children vaccinated with rotavirus vaccine.Influenza vaccine effectiveness in preventing influenza A(H3N2)-related hospitalizations in adults targeted for vaccination by type of vaccine: a hospital-based test-negative study, 2011-2012 A(H3N2) predominant influenza season, Valencia, Spain.Herpes zoster surveillance using electronic databases in the Valencian Community (Spain).Ethical considerations of universal vaccination against human papilloma virusEffectiveness of rotavirus vaccines, licensed but not funded, against rotavirus hospitalizations in the Valencia Region, Spain.Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain.Intussusception following rotavirus vaccination in the Valencia Region, Spain.Genetic characterization of influenza viruses from influenza-related hospital admissions in the St. Petersburg and Valencia sites of the Global Influenza Hospital Surveillance Network during the 2013/14 influenza season.Determinants of seasonal influenza vaccination in pregnant women in Valencia, Spain.Long-term impact of self-financed rotavirus vaccines on rotavirus-associated hospitalizations and costs in the Valencia Region, SpainIt is time to abandon "expected bladder capacity." Systematic review and new models for children's normal maximum voided volumes.A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants.Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured with recombinant human albumin.Immunogenicity and reactogenicity of a combined adsorbed tetanus toxoid, low dose diphtheria toxoid, five component acellular pertussis and inactivated polio vaccine in six-year-old children.Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.Antibiotic Use in Children - A Cross-National Analysis of 6 Countries.Safety and tolerability of cell culture-derived and egg-derived trivalent influenza vaccines in 3 to <18-year-old children and adolescents at risk of influenza-related complications.Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age.Drivers for human papillomavirus vaccination in Valencia (Spain).Rotavirus, vaccine failure or diagnostic error?Adverse events after polysaccharide meningococcal A&C vaccine.[Measles, mumps, and rubella vaccine. Resurgence of measles in Europe].Population-based Analysis of Bronchiolitis Epidemiology in Valencia, Spain.A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.[Serological survey of measles, rubella and mumps immunity among pediatric and resident physicians, Valencia, Spain].Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015.Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
P50
Q26852865-30A7ECDC-B817-4422-B52D-9EC45D57080DQ30353681-44FCA571-8232-439A-A27D-A990F08BBD26Q30371445-15FAE1E3-ECA8-4DB1-8B5D-027047D693E6Q30387842-D7AF13DF-E5BE-4488-9110-3C9A9F249C49Q33574978-9B3F6336-4EE4-43B2-AC40-7C9734EEE34FQ33609246-BDE7684F-D1BF-4531-AF89-4330216BF868Q33653590-0167B47C-EC80-441B-94C2-703364E775C6Q33772320-8AC9479E-60E7-4CB7-B47B-6B94F1FE61B6Q33792393-A68EC54B-21AE-479D-8430-1FD633AE7382Q33799111-391EEA39-D1CB-448D-A75C-76D3CDC6E3ECQ34287906-0FC6C770-F756-45F1-B11F-0A5622FE8E8FQ34350440-8596B509-1F90-4655-8046-8E97B817A593Q34505958-0C6158C6-570F-414D-9814-269206234897Q35008196-E51EDE04-973C-49A2-92DC-83346AB1A1C8Q35141381-54E92001-7766-439D-95EC-D8BDA000BE57Q35154120-24670EAD-6E73-4DDA-A3DF-4CBD32458820Q35607755-AB9E84C9-D3D2-4204-A7FF-EA5ADB51535CQ35896246-A0D87A69-8857-48FF-B992-5D086E08E649Q36149881-69C523F4-51EF-46B7-89E5-92F422212A41Q36200178-3F3E7DEA-9CC3-42FD-86FD-4958D5B762A0Q36343746-12B653CE-DB07-43FA-8441-1ABF93998989Q38121044-A717766D-373C-4AC2-8E48-16D099FCB138Q38235428-2C79DC4B-44EC-47BF-AD35-FF3978C50CAEQ38468409-CF5CFF42-70DA-4362-A2B8-E3A81948E9A5Q38474889-A6D46582-D812-4D35-A77F-517B5DB00775Q38476215-E0ED9930-B9CC-4988-8DED-46B7DD72F664Q39066713-695D324C-D30D-4491-B6BE-1E9FE4C96E82Q40099684-3A22E35D-D8DF-41CE-8BE1-7B53D93F9A12Q40118486-2902A34F-D271-48B4-9E67-6BDB79E83FC3Q40118486-5634747E-5EF7-4925-BFD8-D8D8E86A457DQ40121655-EBDF6ACE-107C-4D2A-AF7C-9DC753A1A879Q40479048-AC7A6741-05A0-438D-AD2B-91E9728C735FQ40639616-8477F4EA-2279-42CC-A8C5-51E7EB437CE5Q40893755-7D16CD23-76C6-4DB9-BEAF-29601A4731F5Q41057753-DDEF03B9-3E77-4DE3-91E3-F9C096AD199AQ41151166-7E5B5E49-FFE3-4316-AB02-463343E0C533Q41696243-514B5C8F-B13E-426E-BBE8-DD3163A5F0DEQ41931409-C4F7E3E0-FD3A-475A-9329-6E9FD0175FECQ42145566-7E834255-5EEC-4122-9B38-7CE1E7BCB0ADQ42175765-041E3539-BC89-4E4A-B60A-EF9B4C5BA8E7
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Javier Diez-Domingo
@ast
Javier Diez-Domingo
@en
Javier Diez-Domingo
@es
Javier Diez-Domingo
@nl
Javier Diez-Domingo
@sl
type
label
Javier Diez-Domingo
@ast
Javier Diez-Domingo
@en
Javier Diez-Domingo
@es
Javier Diez-Domingo
@nl
Javier Diez-Domingo
@sl
prefLabel
Javier Diez-Domingo
@ast
Javier Diez-Domingo
@en
Javier Diez-Domingo
@es
Javier Diez-Domingo
@nl
Javier Diez-Domingo
@sl
P106
P1153
55107272400
P21
P31
P496
0000-0003-1008-3922